- Facing pharmacy trends for the remainder of the year
- Senate passes Drug Quality and Security Act
- On the heels of Q3, Walgreens outlines shift in front-end strategy and pharmacy tailwinds looking forward
- Kathleen Sebelius cites pharmacists' importance as Rite Aid CEO introduces Obamacare resource program
- NACDS, NCPA, GPhA express support for Drug Quality and Security Act
JERUSALEM — Drug maker Teva on Tuesday said its North American sales during the fourth quarter ended Dec. 31 drove the drug maker's financial well-being.
Sales in North America for the fourth quarter reached $2.5 billion, accounting for 56% of total sales and representing an increase of 7% compared with the year-ago period. U.S. generic sales may have dropped 5% to $1.3 billion, but Teva noted that key contributors to the quarter's sales included continued strong sales of generic versions of Effexor XR (venlafaxine) and Pulmicort Respules (budesonide), as well as continued solid sales of Copaxone.
For the full year, Teva said its North American sales rose 16% to nearly $10 billion.
Overall sales for the company reached nearly $4.42 billion in the fourth quarter, a 16% increase, while full-year sales rose to $16.1 billion from $13.9 billion in 2009.